Mersana Therapeutics, Inc. (MRSN) |
|
8.7 0.06 (0.69%)
|
06-09 13:37 |
|
Open: |
8.67 |
Pre. Close: |
8.64 |
|
High:
|
8.81 |
Low:
|
8.45 |
|
Volume:
|
676,095 |
Market Cap:
|
995(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 1:16:25 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 10.45 One year: 12.2 |
| Support: |
Support1: 7.65 Support2: 6.85 |
| Resistance: |
Resistance1: 8.94 Resistance2: 10.45 |
| Pivot: |
7.9 |
| Moving Average: |
MA(5): 8.66 MA(20): 7.86
MA(100): 5.89 MA(250): 6.16 |
| MACD: |
MACD(12,26): 0.6 Signal(9): 0.6 |
| Stochastic oscillator: |
%K(14,3): 84.4  %D(3): 88.3 |
| RSI: |
RSI(14): 68.8 |
| 52-week: |
High: 8.94 Low: 2.91 |
| Average Vol(K): |
3-Month: 1,893 (K) 10-Days: 1,679 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRSN ] has closed below upper band by 15.5%. Bollinger Bands are 23.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.73 - 8.77 |
8.77 - 8.8 |
|
Low:
|
8.32 - 8.36 |
8.36 - 8.39 |
|
Close:
|
8.57 - 8.64 |
8.64 - 8.7 |
|
Company Description |
|
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Fri, 09 Jun 2023
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment? - Simply Wall St
Thu, 08 Jun 2023
JP Morgan slashes price target on Mersana Therapeutics Inc ... - The DBT News
Wed, 07 Jun 2023
Validea Detailed Fundamental Analysis - MRSN - Nasdaq
Mon, 05 Jun 2023
Is Mersana Therapeutics Inc (MRSN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Wed, 31 May 2023
Can Mersana Therapeutics Inc (MRSN) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver
Sun, 28 May 2023
Opaleye Management Inc. Decreases Stock Holdings in Mersana ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
114 (M) |
| Shares Float |
88 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
99.5 (%) |
|
Shares Short
|
6,490 (K) |
|
Shares Short P.Month
|
7,260 (K) |
Stock Financials |
|
EPS
|
-2.26 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.58 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-664.8 |
|
Return on Assets (ttm)
|
-48.5 |
|
Return on Equity (ttm)
|
-208.2 |
|
Qtrly Rev. Growth
|
283.2 |
|
Gross Profit (p.s.)
|
-1.29 |
|
Sales Per Share
|
0.28 |
|
EBITDA (p.s.)
|
-1.88 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-70 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
-3.84 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
14.7 |
|
Price to Sales
|
30.67 |
|
Price to Cash Flow
|
-14.1 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
